Tempest Therapeutics shares are trading higher after the company announced feedback from its end-of-Phase 2 meeting with the FDA for amezalpat in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma.
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics shares are trading higher following positive feedback from the FDA on their end-of-Phase 2 meeting for amezalpat in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma.

August 15, 2024 | 2:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tempest Therapeutics shares are trading higher after receiving positive feedback from the FDA on their end-of-Phase 2 meeting for amezalpat in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma.
The positive feedback from the FDA is a significant milestone for Tempest Therapeutics, indicating potential progress towards approval and commercialization of their treatment. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100